A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study

[1]  C. Dickinson,et al.  The G cell. , 2020, Annual review of physiology.

[2]  D. Schrag,et al.  Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis , 2015, Gut.

[3]  R. Bostick,et al.  Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: A longitudinal study , 2015, International journal of cancer.

[4]  J. Y. Lee,et al.  Correlations Among Endoscopic, Histologic and Serologic Diagnoses for the Assessment of Atrophic Gastritis , 2014, Journal of cancer prevention.

[5]  Yuan Yuan,et al.  Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of histological gastritis, mucosal bacterial density, and levels of serum biomarkers , 2014, Scandinavian journal of gastroenterology.

[6]  Yuan Yuan.  [Population-based gastric cancer screening in Zhuanghe, Liaoning, from 1997 to 2011]. , 2012, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[7]  T. Ninomiya,et al.  Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study , 2012, Scandinavian journal of gastroenterology.

[8]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[9]  Xianghong Zhang,et al.  Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14‐year follow up result in a rural Chinese community , 2012, International journal of cancer.

[10]  Yuan Yuan,et al.  Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. , 2012, World journal of gastroenterology.

[11]  K. Miki.  Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method” , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[12]  S. Moss,et al.  Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. , 2011, Cancer letters.

[13]  N. Rothman,et al.  Plasma pepsinogens, antibodies against Helicobacter pylori, and risk of gastric cancer in the Shanghai Women's Health Study Cohort , 2011, British Journal of Cancer.

[14]  L. Kupčinskas,et al.  The Validity of a Biomarker Method for Indirect Detection of Gastric Mucosal Atrophy Versus Standard Histopathology , 2009, Digestive Diseases and Sciences.

[15]  M. Fujishiro,et al.  LONG‐TERM RESULTS OF GASTRIC CANCER SCREENING USING THE SERUM PEPSINOGEN TEST METHOD AMONG AN ASYMPTOMATIC MIDDLE‐AGED JAPANESE POPULATION , 2009, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[16]  C. Abnet,et al.  Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort , 2009, Gut.

[17]  N. Yoshimura,et al.  Cancer High-Risk Subjects Identified by Serum Pepsinogen Tests: Outcomes after 10-Year Follow-up in Asymptomatic Middle-Aged Males , 2008, Cancer Epidemiology Biomarkers & Prevention.

[18]  Khean Lee Goh,et al.  Screening for gastric cancer in Asia: current evidence and practice. , 2008, The Lancet. Oncology.

[19]  M. Vieth,et al.  Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study , 2008, Scandinavian journal of gastroenterology.

[20]  M. Rugge.  Secondary prevention of gastric cancer , 2007, Gut.

[21]  S. Vollset,et al.  Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status , 2007, Gut.

[22]  S. Xiao,et al.  Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin‐17 and Helicobacter pylori immunoglobulin G antibodies , 2007, Journal of digestive diseases.

[23]  D. Graham,et al.  Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: Application of plasma biomarkers , 2007, Scandinavian journal of gastroenterology.

[24]  A. Aromaa,et al.  Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: Changes in the risk with extended follow‐up period , 2006, International journal of cancer.

[25]  M. Inoue,et al.  Effect of Helicobacter pylori Infection Combined with CagA and Pepsinogen Status on Gastric Cancer Development among Japanese Men and Women: A Nested Case-Control Study , 2006, Cancer Epidemiology Biomarkers & Prevention.

[26]  M. Kubo,et al.  The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. , 2006, American journal of epidemiology.

[27]  Y. Yamaji,et al.  Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study , 2005, Gut.

[28]  M. Rasmussen,et al.  Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study , 2003, European journal of gastroenterology & hepatology.

[29]  K. Miki.  Gastric cancer screening using the serum pepsinogen test method , 2002, Gastric Cancer.

[30]  P. Malfertheiner,et al.  Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report , 2002, Alimentary pharmacology & therapeutics.

[31]  P. Sipponen,et al.  Atrophic Gastritis Serum Levels of Amidated Gastrin-17 and Pepsinogen I in Atrophic Gastritis: An Observational Case-Control Study , 2002, Scandinavian journal of gastroenterology.

[32]  L. Hansson,et al.  Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. , 2001, Gastroenterology.

[33]  A. Helicobacter,et al.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts , 2001, Gut.

[34]  M. Granström,et al.  Clinical symptoms and social factors in a cohort of children spontaneously clearing Helicobacter pylori infection , 1999, Acta paediatrica.

[35]  R. Hunt,et al.  Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. , 1998, Gastroenterology.

[36]  N. Talley,et al.  Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implications. , 1997, The American journal of gastroenterology.

[37]  M F Dixon,et al.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. , 1996, The American journal of surgical pathology.

[38]  K. Ishikawa,et al.  Clinical Application of Serum Pepsinogen I and II Levels for Mass Screening to Detect Gastric Cancer , 1993, Japanese journal of cancer research : Gann.

[39]  P. Correa,et al.  Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. , 1992, Cancer research.

[40]  P. Sipponen,et al.  Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects. , 1990, Scandinavian journal of gastroenterology.

[41]  M. Ishizaki,et al.  In Situ Localization of Pepsinogens I and II mRNA in Human Gastric Mucosa , 1989, Acta pathologica japonica.

[42]  J. Rotter,et al.  Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. , 1982, Gastroenterology.

[43]  I. Samloff.  Pepsinogens, pepsins, and pepsin inhibitors. , 1971, Gastroenterology.

[44]  K. Syrjänen,et al.  Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. , 2016, Anticancer research.

[45]  T. Wang,et al.  Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. , 2000, Gastroenterology.